ReviewCancers2019
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC).
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Transcatheter arterial chemoembolization combined with stereotactic body radiation therapy versus transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.Journal of translational medicine · 2025Trial
- Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma.Scientific reports · 2025Trial
- Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.Computational and mathematical methods in medicine · 2022Trial
- Koumine's Therapeutic Impact on Hepatocellular Carcinoma: A Combined Network Pharmacology and Experimental Study.Biomedicines · 2026Article
- Histotripsy for liver tumours: a systematic review and meta-analysis of current clinical evidence.EClinicalMedicine · 2026Article
- Early adoption of image-guided histotripsy therapy in interventional oncology: challenges and opportunities in the United Kingdom.The British journal of radiology · 2026Review
- Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.Molecular and clinical oncology · 2025Article
- Sorafenib with or without co-interventions for hepatocellular carcinoma.The Cochrane database of systematic reviews · 2025Review
- Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).Liver cancer · 2025Review
- Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discover oncology · 2025Review
- Comparative efficacy of transarterial chemoembolization with and without PD-1 inhibitor in the treatment of unresectable liver cancer and construction and validation of prognostic models.Translational cancer research · 2025Article
- Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy.Journal of hepatocellular carcinoma · 2025Article
- Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid-derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications.Immunity, inflammation and disease · 2024Article
- Melatonin enhances the efficacy of anti-PD-L1 by improving hypoxia in residual tumors after insufficient radiofrequency ablation.Journal of pharmaceutical analysis · 2024Article
- Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.Liver cancer · 2024Article
- Symptoms experienced after transcatheter arterial chemoembolization in patients with primary liver cancer: A network analysis.Asia-Pacific journal of oncology nursing · 2024Article
- Preclinical and phase I studies of an antisense oligonucleotide drug targetingFuture oncology (London, England) · 2024Article
- The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing set of liver-directed therapies (LDT) have become an integral part of hepatocellular carcinoma (HCC) treatment. These range from percutaneous ablative techniques to arterial embolization, and varied radiotherapy strategies. They are now used for local disease control, symptom palliation, and bold curative strategies. The big challenge in the face of these innovative and sometimes overlapping technologies is to identify the best opportunity of use. In real practice, many patients may take benefit from LDT used as a bridge to curative treatment such as resection and liver transplantation. Varying trans-arterial embolization strategies are used, and comparison between established and developing technologies is scarce. Also, radioembolization utilizing yttrium-90 (Y-90) for locally advanced or intermediate-stage HCC needs further evidence of clinical efficacy. There is increasing interest on LDT-led changes in tumor biology that could have implications in systemic therapy efficacy. Foremost, additional to its apoptotic and necrotic properties, LDT could warrant changes in vascular endothelial growth factor (VEGF) expression and release. However, trans-arterial chemoembolization (TACE) used alongside tyrosine-kinase inhibitor (TKI) sorafenib has had its efficacy contested. Most recently, interest in associating Y-90 and TKI has emerged. Furthermore, LDT-led differences in tumor immune microenvironment and immune cell infiltration could be an opportunity to enhance immunotherapy efficacy for HCC patients. Early attempts to coordinate LDT and immunotherapy are being made. We here review LDT techniques exposing current evidence to understand its extant reach and future applications alongside systemic therapy development for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.